Loading the page…
Nasdaq 100
REGN
Regeneron Pharmaceuticals, Inc., Health Care
$927.89
+13.33% on the day
Close of Fri, Oct 30, 2026
+21.8% over 3M
2026-07-312026-09-162026-10-30
Market cap$95.5B
Last close$927.89
Day move+13.33%
Nasdaq 100
Regeneron Pharmaceuticals, Inc., Health Care
$927.89
+13.33% on the day
Close of Fri, Oct 30, 2026
| Quarter ending | Jun 2026 | Mar 2026 | Dec 2025* | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024* | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3B | $3.6B | $3.9B | $3.8B | $3.7B | $3.0B | $3.8B | $3.7B |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 30.1% | 17.8% | 22.7% | 27.3% | 29.4% | 19.5% | 26.1% | 31.7% |
| Net margin | 30.2% | 20.2% | 21.7% | 38.9% | 37.9% | 26.7% | 24.2% | 36.0% |
| EPS, diluted | $12.23 | $6.75 | $7.78 | $13.62 | $12.81 | $7.27 | $8.12 | $11.54 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
| Measure | REGN | Higher than |
|---|---|---|
| Earnings yield (earnings ÷ price) | 4.4% | 70% |
| Book yield (book value ÷ price) | 32.2% | 83% |
| Free cash flow yield | 5.1% | 75% |
| Buyback yield | 3.5% | 88% |
| Revenue growth, a year | 1.0% | 11% |
| EPS growth, a year | 8.2% | 44% |
| Return on equity | 13.7% | 34% |
| Return on assets | 10.4% | 55% |
| Net margin | 27.9% |
Research
Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
| 76% |
| Liabilities ÷ assets | 24.0% | 12% |
|---|
| Past year, skipping last month | 13.1% | 53% |
|---|
| Past 6 months, skipping last month | 5.0% | 56% |
|---|
| Volatility, a year's worth | 37.6% | 49% |
|---|
"Higher than" is the share of the 100 with a lower figure. Financial figures from SEC filings, market figures from daily closes. Dividend yield and beta are under Valuation below.
Picked by YouTube search, not by us. Someone else's view, not advice.
Regeneron (REGN) Stock Looks At A Discount To EarningsSimply Wall St., 4h agoWhy Regeneron Shares Are In Focus After Strong EarningsSimply Wall St., 5h ago
Regeneron: 3 Key Takeaways for Long-Term InvestorsMotley Fool, 7h ago
Regeneron Stock Just Hit a 2-Year High. Here's Why.Barchart, 7h agoRegeneron Pharmaceuticals (REGN) Jumped, But What Is The Market Seeing Now?Simply Wall St., 11h agoHeadlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Beat the forecast in 4 of the last 4 quarters.
The stock's move is from the close before the report to the close after it.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
From Yahoo Finance, regeneron.com
Regeneron (REGN) Stock Looks At A Discount To EarningsSimply Wall St., 4h agoWhy Regeneron Shares Are In Focus After Strong EarningsSimply Wall St., 5h agoRegeneron: 3 Key Takeaways for Long-Term InvestorsMotley Fool, 7h agoRegeneron Stock Just Hit a 2-Year High. Here's Why.Barchart, 7h agoRegeneron Pharmaceuticals (REGN) Jumped, But What Is The Market Seeing Now?Simply Wall St., 11h ago
Regeneron (REGN) stock trades up, here is whyStockStory, 12h ago
Regeneron Pharmaceuticals Inc (REGN) Q3 2026 Earnings Call Highlights: Record Dupixent and ...GuruFocus.com, 21h ago
Regeneron Bolts 13% Higher, Breaking Out To A Two-Year High On Dupixent DominanceInvestor's Business Daily, Oct 30US Equity Markets End Lower After Sell-Off in Technology StocksMT Newswires, Oct 30
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock UpZacks, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
Every transaction, in AdvancedSEC Form 4, public domain. The latest 40 of 45 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | Murphy Andrew JCo-Chief Scientific Officer | Sold on the market10b5-1 plan | −4,147 | $772.70average | $3.2M | Form 4 ↗ |
| Oct 13, 2026 | Murphy Andrew JCo-Chief Scientific Officer | Option exercise | +17,000 | $381.92 | $6.5M | Form 4 ↗ |
| Oct 13, 2026 | Murphy Andrew JCo-Chief Scientific Officer | Tax withholding | −12,853 | $754.58 | $9.7M | Form 4 ↗ |
| Sep 3, 2026 | McCourt MarionEVP Commercial | Sold on the market10b5-1 plan | −1,131 | $857.39 | $970K | Form 4 ↗ |
| Sep 2, 2026 | McCourt MarionEVP Commercial | Sold on the market10b5-1 plan | −1,215 | $850.00 | $1.0M | Form 4 ↗ |
| Sep 2, 2026 | Guarini KathrynDirector | Option exercise | +400 | $719.37 | $288K | Form 4 ↗ |
| Sep 2, 2026 | Guarini KathrynDirector | Sold on the market10b5-1 plan | −400 | $850.00 | $340K | Form 4 ↗ |
| Aug 19, 2026 | Larosa Joseph JEVP General Counsel and Secret | Option exercise | +12,282 | $381.92 | $4.7M | Form 4 ↗ |
| Aug 19, 2026 | Larosa Joseph JEVP General Counsel and Secret | Tax withholding | −9,019 | $830.15 | $7.5M | Form 4 ↗ |
| Aug 18, 2026 | Fenimore Christopher R.EVP Finance CFO | Option exercise | +6,283 | $381.92 | $2.4M | Form 4 ↗ |
| Aug 18, 2026 | Fenimore Christopher R.EVP Finance CFO | Tax withholding | −4,599 | $813.47 | $3.7M | Form 4 ↗ |
| Aug 10, 2026 | Guarini KathrynDirector | Option exercise | +400 | $719.37 | $288K | Form 4 ↗ |
| Aug 10, 2026 | Guarini KathrynDirector | Sold on the market10b5-1 plan | −400 | $800.00 | $320K | Form 4 ↗ |
| Aug 10, 2026 | Zoghbi Huda YDirector | Option exercise | +800 | $376.69 | $301K | Form 4 ↗ |
| Aug 10, 2026 | Zoghbi Huda YDirector | Sold on the market10b5-1 plan | −800 | $800.00 | $640K | Form 4 ↗ |
| Jul 2, 2026 | Ryan Arthur FDirector | Sold on the market10b5-1 plan | −200 | $650.15 | $130K | Form 4 ↗ |
| May 1, 2026 | Ryan Arthur FDirector | Sold on the market10b5-1 plan | −100 | $705.24average | $70.5K | Form 4 ↗ |
| Apr 1, 2026 | Ryan Arthur FDirector | Sold on the market10b5-1 plan | −100 | $777.27average | $77.7K | Form 4 ↗ |
| Mar 2, 2026 | Ryan Arthur FDirector | Sold on the market10b5-1 plan | −100 | $785.50average | $78.5K | Form 4 ↗ |
| Feb 19, 2026 | Zoghbi Huda YDirector | Option exercise | +1,638 | $376.69 | $617K | Form 4 ↗ |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sold on the market10b5-1 plan | −1,638 | $781.33average | $1.3M | Form 4 ↗ |
| Feb 9, 2026 | Pitofsky JasonSVP Controller | Option exercise | +1,000 | $492.00 | $492K | Form 4 ↗ |
| Feb 9, 2026 | Pitofsky JasonSVP Controller | Sold on the market10b5-1 plan | −2,036 | $778.52average | $1.6M | Form 4 ↗ |
| Feb 9, 2026 | Ryan Arthur FDirector | Sold on the market10b5-1 plan | −100 | $778.53average | $77.9K | Form 4 ↗ |
| Jan 7, 2026 | Bassler Bonnie LDirector | Option exercise | +1,500 | $374.12 | $561K | Form 4 ↗ |
| Jan 7, 2026 | Bassler Bonnie LDirector | Sold on the market10b5-1 plan | −1,500 | $800.00 | $1.2M | Form 4 ↗ |
| Jan 2, 2026 | Zoghbi Huda YDirector | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Zoghbi Huda YDirector | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Thompson Craig B.Director | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Thompson Craig B.Director | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Sing George LDirector | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Sing George LDirector | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Guarini KathrynDirector | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Guarini KathrynDirector | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Schenkein David PDirector | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Schenkein David PDirector | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Goldstein Joseph LDirector | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Goldstein Joseph LDirector | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Ryan Arthur FDirector | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Ryan Arthur FDirector | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Coles N AnthonyDirector | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Coles N AnthonyDirector | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Brown Michael SDirector | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Brown Michael SDirector | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Bassler Bonnie LDirector | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Bassler Bonnie LDirector | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Poon Christine ADirector | Award | +155 | — | — | Form 4 ↗ |
| Jan 2, 2026 | Poon Christine ADirector | AwardNon-Qualified Stock Option (right to buy) | +1,962 | — | — | Form 4 ↗ |
| Dec 31, 2025 | Yancopoulos GeorgeBd. Co-Chair, President & CSO, Director | Units vested | +28,570 | — | — | Form 4 ↗ |
| Dec 31, 2025 | Yancopoulos GeorgeBd. Co-Chair, President & CSO, Director | Tax withholding | −28,570 | $772.09 | $22.1M | Form 4 ↗ |
| Dec 31, 2025 | Schleifer Leonard SBd. Co-Chair, President & CEO, Director | Units vested | +28,570 | — | — | Form 4 ↗ |
| Dec 31, 2025 | Schleifer Leonard SBd. Co-Chair, President & CEO, Director | Tax withholding | −28,570 | $772.09 | $22.1M | Form 4 ↗ |
| Dec 30, 2025 | Sing George LDirector | Option exercise | +9,212 | $520.01 | $4.8M | Form 4 ↗ |
| Dec 30, 2025 | Sing George LDirector | Tax withholding | −6,188 | $774.03 | $4.8M | Form 4 ↗ |
| Dec 9, 2025 | Van Plew Daniel PEVP & General Mgr, Industrial | Tax withholding | −2,552 | $701.51 | $1.8M | Form 4 ↗ |
| Dec 9, 2025 | Murphy Andrew JEVP Research | Tax withholding | −4,229 | $701.51 | $3.0M | Form 4 ↗ |
| Dec 9, 2025 | McCourt MarionEVP Commercial | Tax withholding | −1,021 | $701.51 | $716K | Form 4 ↗ |
| Dec 9, 2025 | Yancopoulos GeorgeBd. Co-Chair, President & CSO, Director | Option exercise | +146,815 | $555.67 | $81.6M | Form 4 ↗ |
| Dec 9, 2025 | Yancopoulos GeorgeBd. Co-Chair, President & CSO, Director | Tax withholding | −131,874 | $701.51 | $92.5M | Form 4 ↗ |
| Dec 9, 2025 | Schleifer Leonard SBd. Co-Chair, President & CEO, Director | Option exercise | +172,723 | $555.67 | $96M | Form 4 ↗ |
| Dec 9, 2025 | Schleifer Leonard SBd. Co-Chair, President & CEO, Director | Tax withholding | −155,145 | $701.51 | $109M | Form 4 ↗ |
| Dec 8, 2025 | Pitofsky JasonVP Controller | Tax withholding | −989 | $712.94 | $705K | Form 4 ↗ |
| Dec 8, 2025 | Van Plew Daniel PEVP & General Mgr, Industrial | Tax withholding | −1,906 | $712.94 | $1.4M | Form 4 ↗ |
| Dec 8, 2025 | Murphy Andrew JEVP Research | Tax withholding | −1,699 | $712.94 | $1.2M | Form 4 ↗ |
| Dec 8, 2025 | McCourt MarionEVP Commercial | Tax withholding | −1,336 | $712.94 | $952K | Form 4 ↗ |
| Dec 8, 2025 | Larosa Joseph JEVP General Counsel and Secret | Tax withholding | −1,396 | $712.94 | $995K | Form 4 ↗ |
| Dec 8, 2025 | Fenimore Christopher R.EVP Finance CFO | Tax withholding | −992 | $712.94 | $707K | Form 4 ↗ |
| Dec 5, 2025 | Pitofsky JasonVP Controller | Award | +2,064 | — | — | Form 4 ↗ |
| Dec 5, 2025 | Pitofsky JasonVP Controller | AwardNon-Qualified Stock Option (right to buy) | +2,261 | — | — | Form 4 ↗ |
| Dec 5, 2025 | Van Plew Daniel PEVP & General Mgr, Industrial | Award | +3,715 | — | — | Form 4 ↗ |
| Dec 5, 2025 | Van Plew Daniel PEVP & General Mgr, Industrial | AwardNon-Qualified Stock Option (right to buy) | +18,315 | — | — | Form 4 ↗ |
| Dec 5, 2025 | Murphy Andrew JEVP Research | Award | +3,715 | — | — | Form 4 ↗ |
| Dec 5, 2025 | Murphy Andrew JEVP Research | AwardNon-Qualified Stock Option (right to buy) | +18,315 | — | — | Form 4 ↗ |
| Dec 5, 2025 | McCourt MarionEVP Commercial | Award | +2,476 | — | — | Form 4 ↗ |
| Dec 5, 2025 | McCourt MarionEVP Commercial | AwardNon-Qualified Stock Option (right to buy) | +12,210 | — | — | Form 4 ↗ |
| Dec 5, 2025 | Larosa Joseph JEVP General Counsel and Secret | Award | +2,476 | — | — | Form 4 ↗ |
| Dec 5, 2025 | Larosa Joseph JEVP General Counsel and Secret | AwardNon-Qualified Stock Option (right to buy) | +12,210 | — | — | Form 4 ↗ |
| Dec 5, 2025 | Fenimore Christopher R.EVP Finance CFO | Award | +3,027 | — | — | Form 4 ↗ |
| Dec 5, 2025 | Fenimore Christopher R.EVP Finance CFO | AwardNon-Qualified Stock Option (right to buy) | +14,924 | — | — | Form 4 ↗ |
SEC Form 4, public domain. The latest 40 of 45 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR